Cancer Family
Intestinal Neoplasm
CI-CAN-00000209Explore in graph →
Non-malignant1,892 active trials21 approved drugs383 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000209Explore in graph →
Clinical trials
9,155 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01671488 | A Phase I/II Evaluation of ADXS11-001, Mitomycin, 5-fluorouracil (5-FU) and IMRT for Anal Cancer(276) | terminated | Phase 1 / Phase 2 | 11 | Brown UniversityOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT02576665 | A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6) | terminated | Phase 1 | 21 | Tocagen Inc.INDUSTRY | 1 | Feb 7, 2020 | clinicaltrials |
| NCT02014116 | A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body | terminated | Phase 1 | 51 | Eli Lilly and CompanyINDUSTRY | 4 | Dec 27, 2019 | clinicaltrials |
| NCT01336985 | Safety and Pharmacokinetics of Treating Liver Cancer With Drug-Eluting Beads | terminated | Phase 1 | 5 | National Institutes of Health Clinical Center (CC)NIH | 1 | Dec 17, 2019 | clinicaltrials |
| NCT02318901 | Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer(PembroMab) | terminated | Phase 1 / Phase 2 | 16 | Western Regional Medical CenterOTHER | 1 | Oct 21, 2019 | clinicaltrials |
| NCT03204201 | Validation of ICG to Identify the Urethra During Rectal Surgery | terminated | Phase 1 / Phase 2 | 5 | Oxford University Hospitals NHS TrustOTHER | 1 | Aug 13, 2019 | clinicaltrials |
| NCT03204994 | Fluorescence Targeted Pelvic Lymph Node Mapping | terminated | Phase 1 / Phase 2 | 1 | Oxford University Hospitals NHS TrustOTHER | 1 | Aug 13, 2019 | clinicaltrials |
| NCT03677960 | Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection | terminated | Phase 1 | 6 | Antiva BiosciencesINDUSTRY | 2 | Jul 24, 2019 | clinicaltrials |
| NCT02952989 | A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors | terminated | Phase 1 | 47 | Seagen Inc.INDUSTRY | 1 | Jul 19, 2019 | clinicaltrials |
| NCT03431311 | T Cell Receptor Based Therapy of Metastatic Colorectal Cancer(TCR-CRC-001) | terminated | Phase 1 / Phase 2 | 1 | Oslo University HospitalOTHER | 1 | Jun 13, 2019 | clinicaltrials |
| NCT00403052 | A Study of 1018 Immunostimulatory Sequence (ISS) Administered With Irinotecan and Cetuximab to Treat Patients With Previously Treated Metastatic Colorectal Cancer | terminated | Phase 1 | 14 | Dynavax Technologies CorporationINDUSTRY | 1 | Apr 16, 2019 | clinicaltrials |
| NCT02568046 | Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients | terminated | Phase 1 / Phase 2 | 10 | Symphogen A/SINDUSTRY | 2 | Mar 26, 2019 | clinicaltrials |
| NCT02991196 | Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal Cancer | terminated | Phase 1 | 4 | Daiichi SankyoINDUSTRY | 1 | Feb 12, 2019 | clinicaltrials |
| NCT01871311 | A Phase I Study of Nilontinib and Cetuximab in Patients With Solid Tumors | terminated | Phase 1 | 15 | Georgetown UniversityOTHER | 1 | Feb 8, 2019 | clinicaltrials |
| NCT02205398 | Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy | terminated | Phase 1 | 13 | Novartis PharmaceuticalsINDUSTRY | 7 | Jan 22, 2019 | clinicaltrials |
| NCT02726334 | A Phase I, Dose Escalation Study of BNC101 in Patients With Metastatic Colorectal Cancer. | terminated | Phase 1 | 22 | Bionomics LimitedINDUSTRY | 1 | Jan 16, 2019 | clinicaltrials |
| NCT02650635 | TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors | terminated | Phase 1 | 4 | Mayo ClinicOTHER | 1 | Sep 5, 2018 | clinicaltrials |
| NCT02611661 | Local Ablative Strategies After Endovascular Radioembolization(LASER) | terminated | Phase 1 | 9 | Washington University School of MedicineOTHER | 1 | Aug 16, 2018 | clinicaltrials |
| NCT01197664 | Paricalcitol, Fluorouracil, and Radiation Therapy in Treating Patients With Rectal Cancer That Can Be Removed in Surgery | terminated | Phase 1 | 2 | Wake Forest University Health SciencesOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT02168907 | CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | terminated | Phase 1 | 1 | Wake Forest University Health SciencesOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT02423954 | Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)(NivoPlus) | terminated | Phase 1 / Phase 2 | 33 | Western Regional Medical CenterOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT00827580 | Eniluracil Hand Foot Syndrome | terminated | Phase 1 | 3 | West Virginia UniversityOTHER | 1 | May 30, 2018 | clinicaltrials |
| NCT03253185 | A Study of SC-007 in Subjects With Advanced Cancer | terminated | Phase 1 | 7 | AbbVieINDUSTRY | 1 | Apr 27, 2018 | clinicaltrials |
| NCT02577588 | Trial of Adoptive T Cell Therapy With Activated P53 Specific T Cells for Treatment of Advanced Colorectal Cancer(ATACC) | terminated | Phase 1 | 1 | National Center for Tumor Diseases, HeidelbergOTHER | 1 | Apr 11, 2018 | clinicaltrials |
| NCT02110953 | Irinotecan-Eluting Beads in Treating Patients With Refractory Metastatic Colon or Rectal Cancer That Has Spread to the Liver | terminated | Phase 1 | 2 | Fox Chase Cancer CenterOTHER | 1 | Feb 26, 2018 | clinicaltrials |
| NCT01012362 | Study of Pazopanib and Ixabepilone in Patients With Solid Tumors | terminated | Phase 1 | 31 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT00226941 | A Phase 1-2 Trial of Cetuximab in Combination With Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgery for Locally-advanced Rectal Cancer | terminated | Phase 1 / Phase 2 | 23 | George Albert FisherOTHER | 1 | Dec 8, 2017 | clinicaltrials |
| NCT02538627 | Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib | terminated | Phase 1 | 5 | Merrimack PharmaceuticalsINDUSTRY | 1 | Sep 5, 2017 | clinicaltrials |
| NCT00361244 | SU011248 in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Stage IV Colorectal Cancer | terminated | Phase 1 / Phase 2 | 6 | Massachusetts General HospitalOTHER | 1 | Feb 17, 2017 | clinicaltrials |
| NCT00072098 | Interleukin-12 Gene in Treating Patients With Liver Metastases Secondary to Colorectal Cancer | terminated | Phase 1 | 22 | Max SungOTHER | 1 | Jan 11, 2017 | clinicaltrials |
| NCT02112162 | Gene Expression and FDG PET/MRI in Evaluating Treatment Response in Patients With Locally Advanced Rectal Cancer Undergoing Chemotherapy and Radiation Therapy Before Surgery | terminated | Phase 1 | 2 | Washington University School of MedicineOTHER | 1 | Dec 8, 2016 | clinicaltrials |
| NCT01085331 | MEK Inhibitor MSC1936369B Plus FOLFIRI in Second Line K-Ras Mutated Metastatic Colorectal Cancer (mCRC) | terminated | Phase 1 / Phase 2 | 16 | EMD SeronoINDUSTRY | 3 | Oct 19, 2016 | clinicaltrials |
| NCT01937715 | A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer | terminated | Phase 1 / Phase 2 | 18 | PfizerINDUSTRY | 3 | Aug 18, 2016 | clinicaltrials |
| NCT01111292 | Inositol in Preventing Colorectal Cancer in Patients With Colitis-Associated Dysplasia | terminated | Phase 1 / Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Jul 12, 2016 | clinicaltrials |
| NCT00673322 | Trial of Second Generation Designer T Cells in Colorectal Carcinoma | terminated | Phase 1 | 1 | Roger Williams Medical CenterOTHER | 1 | Jun 17, 2016 | clinicaltrials |
| NCT02720926 | Study of TKI 258 in Combination With Xeloda and Oxaliplatin in Advanced Colorectal and Gastric Cancer | terminated | Phase 1 | 3 | National Cancer Centre, SingaporeOTHER | 1 | Mar 28, 2016 | clinicaltrials |
| NCT01816659 | An Open-Labeled Pilot Study of Biomarker Response Following Short-Term Exposure to Metformin | terminated | Phase 1 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 18, 2015 | clinicaltrials |
| NCT02109224 | Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection | terminated | Phase 1 | 72 | National Cancer Institute (NCI)NIH | 1 | Aug 20, 2015 | clinicaltrials |
| NCT01300858 | A Study of the Safety and Biological Activity of Intraperitoneal (IP) EGEN-001 Administered Alone and in Combination With Standard Chemotherapy in Colorectal Peritoneal Carcinomatosis Patients | terminated | Phase 1 / Phase 2 | 4 | EGEN, Inc.INDUSTRY | 1 | Jul 13, 2015 | clinicaltrials |
| NCT00099346 | MK0457 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Colorectal Cancer and Other Advanced Solid Tumors (0457-001) | terminated | Phase 1 | — | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 17, 2015 | clinicaltrials |
| NCT01238965 | Panobinostat and Fluorouracil Followed By Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer Who Did Not Respond to Previous Fluorouracil-Based Chemotherapy | terminated | Phase 1 | 7 | University of Southern CaliforniaOTHER | 1 | May 27, 2015 | clinicaltrials |
| NCT01198535 | Phase I Study of Cetuximab With RO4929097 in Metastatic Colorectal Cancer | terminated | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | May 18, 2015 | clinicaltrials |
| NCT01440127 | Impact of Pretreatment With Metformin on Colorectal Cancer Stem Cells (CCSC) and Related Pharmacodynamic Markers | terminated | Phase 1 | 9 | Tufts Medical CenterOTHER | 1 | Mar 26, 2015 | clinicaltrials |
| NCT01149434 | Study of JI-101 in Patients With Advanced Low Grade Endocrine Tumors, Ovarian Cancers or K-RAS Mutant Colon Cancers | terminated | Phase 1 / Phase 2 | 19 | University of UtahOTHER | 1 | Oct 6, 2014 | clinicaltrials |
| NCT00089076 | MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma | terminated | Phase 1 / Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | May 30, 2014 | clinicaltrials |
| NCT00933985 | Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia | terminated | Phase 1 | 22 | National Cancer Institute (NCI)NIH | 2 | May 1, 2014 | clinicaltrials |
| NCT01233505 | Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors | terminated | Phase 1 | 16 | National Cancer Institute (NCI)NIH | 1 | Apr 2, 2014 | clinicaltrials |
| NCT00088933 | Vaccine Therapy and Sargramostim With or Without Docetaxel in Treating Patients With Metastatic Lung Cancer or Metastatic Colorectal Cancer | terminated | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Mar 31, 2014 | clinicaltrials |
| NCT00101205 | Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma | terminated | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Feb 24, 2014 | clinicaltrials |
Data updated 22 days agoSource updated Feb 17, 2020source: clinicaltrials